Lucence Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 105

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 9

Lucence General Information

Description

Developer of a precision health platform designed to detect cancer and other age-related diseases earlier through AI-powered liquid biopsy analysis. The company offers multi-omic liquid biopsies integrating ctDNA and ctRNA analysis with artificial intelligence for therapy selection and disease monitoring, enabling clinicians and healthcare providers to identify disease earlier and guide personalized treatment decisions.

Contact Information

Website
www.lucence.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3520 West Bayshore Road
  • Palo Alto, CA 94303
  • United States
+1 (888)
Primary Industry
Decision/Risk Analysis
Other Industries
Other Healthcare Technology Systems
Other Healthcare Services
Vertical(s)
Artificial Intelligence & Machine Learning, HealthTech, Oncology
Corporate Office
  • 3520 West Bayshore Road
  • Palo Alto, CA 94303
  • United States
+1 (888)

Lucence Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lucence Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Secondary Transaction - Private 01-Apr-2025 Completed Generating Revenue
7. Debt - General Completed Generating Revenue
6. Grant 25-Apr-2024 Completed Generating Revenue
5. Later Stage VC 23-May-2023 Completed Generating Revenue
4. Early Stage VC (Series A) 20-Nov-2019 Completed Generating Revenue
3. Seed Round 01-Nov-2017 Completed Generating Revenue
2. Grant 20-Sep-2017 $73.9K Completed Generating Revenue
1. Seed Round 01-Jan-2016 Completed Startup
To view Lucence’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Lucence Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a precision health platform designed to detect cancer and other age-related diseases earlier through AI-pow
Decision/Risk Analysis
Palo Alto, CA
105 As of 2026

Ho Chi Minh City, Vietnam
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Lucence Competitors (6)

One of Lucence’s 6 competitors is Gene Solutions (Laboratory Services (Healthcare)), a Venture Capital-Backed company based in Ho Chi Minh City, Vietnam.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Gene Solutions (Laboratory Services (Healthcare)) Venture Capital-Backed Ho Chi Minh City, Vietnam
Foundation Medicine Formerly VC-backed Boston, MA
GRAIL Formerly VC-backed Menlo Park, CA
Guardant Health Formerly VC-backed Palo Alto, CA
Caris Life Sciences Formerly PE-Backed Irving, TX
To view Lucence’s complete competitors history, request access »

Lucence Patents

  • 48

    Total Documents Applications and Grants

  • Total Patents Families

  • 19

    Granted

  • 11

    Pending

  • Expiring in next 12 mo

Lucence Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026164563-A1 Method of detection of viral and tumor-derived nucleic acids for multi-cancer early detection and cancer recurrence monitoring Pending 31-Jan-2025
US-20260218287-A1 Method for simultaneous multiplex detection of multiple cancer-associated alteration and determination of tissue-of-origin Pending 24-Feb-2023
WO-2024177564-A1 Method for simultaneous multiplex detection of multiple cancer-associated alteration and determination of tissue-of-origin Inactive 24-Feb-2023
EP-4627108-A1 Method for efficient multiplex detection and quantification of genetic alterations Pending 02-Dec-2022
EP-4627108-A4 Method for efficient multiplex detection and quantification of genetic alterations Pending 02-Dec-2022 C12Q1/6858
To view Lucence’s complete patent history, request access »

Lucence Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lucence Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
FedEx Small Business Grant Contest Other
Centurion Investment Management Venture Capital Minority
Openspace Capital Asset Manager Minority
Parkway Holdings PE-Backed Company Minority
IHH Healthcare Holding Company Minority
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

Lucence FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process